Gut microbiota modification suppresses the development of pulmonary arterial hypertension in an SU5416/hypoxia rat model

The pathogenesis of pulmonary arterial hypertension is closely associated with dysregulated inflammation. Recently, abnormal alterations in gut microbiome composition and function were reported in a pulmonary arterial hypertension experimental animal model. However, it remains unclear whether these...

Full description

Bibliographic Details
Main Authors: Takayuki J. Sanada, Koji Hosomi, Hiroki Shoji, Jonguk Park, Akira Naito, Yumiko Ikubo, Asako Yanagisawa, Takayuki Kobayashi, Hideki Miwa, Rika Suda, Seiichiro Sakao, Kenji Mizuguchi, Jun Kunisawa, Nobuhiro Tanabe, Koichiro Tatsumi
Format: Article
Language:English
Published: SAGE Publishing 2020-08-01
Series:Pulmonary Circulation
Online Access:https://doi.org/10.1177/2045894020929147
id doaj-62acc1b6e8c54856bc31082c59760490
record_format Article
spelling doaj-62acc1b6e8c54856bc31082c597604902020-11-25T03:41:37ZengSAGE PublishingPulmonary Circulation2045-89402020-08-011010.1177/2045894020929147Gut microbiota modification suppresses the development of pulmonary arterial hypertension in an SU5416/hypoxia rat modelTakayuki J. Sanada0Koji Hosomi1Hiroki Shoji2Jonguk Park3Akira Naito4Yumiko Ikubo5Asako Yanagisawa6Takayuki Kobayashi7Hideki Miwa8Rika Suda9Seiichiro Sakao10Kenji Mizuguchi11Jun Kunisawa12Nobuhiro Tanabe13Koichiro Tatsumi14Department of Pulmonology, Institute for Cardiovascular Research (ICaR-VU)/VU University Medical Center, Amsterdam, the NetherlandsCenter for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health, and Nutrition, Osaka, JapanDepartment of Respirology, Graduate School of Medicine, Chiba, JapanArtificial Intelligence Center for Health and Biomedical Research, National Institutes of Biomedical Innovation, Health, and Nutrition, Osaka, JapanDepartment of Respirology, Graduate School of Medicine, Chiba, JapanDepartment of Respirology, Graduate School of Medicine, Chiba, JapanDepartment of Respirology, Graduate School of Medicine, Chiba, JapanDepartment of Respirology, Graduate School of Medicine, Chiba, JapanDepartment of Respirology, Graduate School of Medicine, Chiba, JapanDepartment of Respirology, Graduate School of Medicine, Chiba, JapanDepartment of Respirology, Graduate School of Medicine, Chiba, JapanInstitute for Protein Research, Osaka University, Osaka, JapanCenter for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health, and Nutrition, Osaka, JapanDepartment of Respirology, Chibaken Saiseikai Narashino Hospital, Narashino, JapanDepartment of Respirology, Graduate School of Medicine, Chiba, JapanThe pathogenesis of pulmonary arterial hypertension is closely associated with dysregulated inflammation. Recently, abnormal alterations in gut microbiome composition and function were reported in a pulmonary arterial hypertension experimental animal model. However, it remains unclear whether these alterations are a result or the cause of pulmonary arterial hypertension. The purpose of this study was to investigate whether alterations in the gut microbiome affected the hemodynamics in SU5416/hypoxia rats. We used the SU5416/hypoxia rat model in our study. SU5416/hypoxia rats were treated with a single SU5416 injection (30 mg/kg) and a three-week hypoxia exposure (10% O 2 ). Three SU5416/hypoxia rats were treated with a combination of four antibiotics (SU5416/hypoxia + ABx group) for four weeks. Another group was exposed to hypoxia (10% O 2 ) without the SU5416 treatment, and control rats received no treatment. Fecal samples were collected from each animal, and the gut microbiota composition was analyzed by 16S rRNA sequencing. The antibiotic treatment significantly suppressed the vascular remodeling, right ventricular hypertrophy, and increase in the right ventricular systolic pressure in SU5416/hypoxia rats. 16S rRNA sequencing analysis revealed gut microbiota modification in SU5416/hypoxia + ABx group. The Firmicutes-to-Bacteroidetes ratio in SU5416/hypoxia rats was significantly higher than that in control and hypoxia rats. Compared with the control microbiota, 14 bacterial genera, including Bacteroides and Akkermansia , increased, whereas seven bacteria, including Rothia and Prevotellaceae , decreased in abundance in SU5416/hypoxia rats. Antibiotic-induced modification of the gut microbiota suppresses the development of pulmonary arterial hypertension. Dysbiosis may play a causal role in the development and progression of pulmonary arterial hypertension.https://doi.org/10.1177/2045894020929147
collection DOAJ
language English
format Article
sources DOAJ
author Takayuki J. Sanada
Koji Hosomi
Hiroki Shoji
Jonguk Park
Akira Naito
Yumiko Ikubo
Asako Yanagisawa
Takayuki Kobayashi
Hideki Miwa
Rika Suda
Seiichiro Sakao
Kenji Mizuguchi
Jun Kunisawa
Nobuhiro Tanabe
Koichiro Tatsumi
spellingShingle Takayuki J. Sanada
Koji Hosomi
Hiroki Shoji
Jonguk Park
Akira Naito
Yumiko Ikubo
Asako Yanagisawa
Takayuki Kobayashi
Hideki Miwa
Rika Suda
Seiichiro Sakao
Kenji Mizuguchi
Jun Kunisawa
Nobuhiro Tanabe
Koichiro Tatsumi
Gut microbiota modification suppresses the development of pulmonary arterial hypertension in an SU5416/hypoxia rat model
Pulmonary Circulation
author_facet Takayuki J. Sanada
Koji Hosomi
Hiroki Shoji
Jonguk Park
Akira Naito
Yumiko Ikubo
Asako Yanagisawa
Takayuki Kobayashi
Hideki Miwa
Rika Suda
Seiichiro Sakao
Kenji Mizuguchi
Jun Kunisawa
Nobuhiro Tanabe
Koichiro Tatsumi
author_sort Takayuki J. Sanada
title Gut microbiota modification suppresses the development of pulmonary arterial hypertension in an SU5416/hypoxia rat model
title_short Gut microbiota modification suppresses the development of pulmonary arterial hypertension in an SU5416/hypoxia rat model
title_full Gut microbiota modification suppresses the development of pulmonary arterial hypertension in an SU5416/hypoxia rat model
title_fullStr Gut microbiota modification suppresses the development of pulmonary arterial hypertension in an SU5416/hypoxia rat model
title_full_unstemmed Gut microbiota modification suppresses the development of pulmonary arterial hypertension in an SU5416/hypoxia rat model
title_sort gut microbiota modification suppresses the development of pulmonary arterial hypertension in an su5416/hypoxia rat model
publisher SAGE Publishing
series Pulmonary Circulation
issn 2045-8940
publishDate 2020-08-01
description The pathogenesis of pulmonary arterial hypertension is closely associated with dysregulated inflammation. Recently, abnormal alterations in gut microbiome composition and function were reported in a pulmonary arterial hypertension experimental animal model. However, it remains unclear whether these alterations are a result or the cause of pulmonary arterial hypertension. The purpose of this study was to investigate whether alterations in the gut microbiome affected the hemodynamics in SU5416/hypoxia rats. We used the SU5416/hypoxia rat model in our study. SU5416/hypoxia rats were treated with a single SU5416 injection (30 mg/kg) and a three-week hypoxia exposure (10% O 2 ). Three SU5416/hypoxia rats were treated with a combination of four antibiotics (SU5416/hypoxia + ABx group) for four weeks. Another group was exposed to hypoxia (10% O 2 ) without the SU5416 treatment, and control rats received no treatment. Fecal samples were collected from each animal, and the gut microbiota composition was analyzed by 16S rRNA sequencing. The antibiotic treatment significantly suppressed the vascular remodeling, right ventricular hypertrophy, and increase in the right ventricular systolic pressure in SU5416/hypoxia rats. 16S rRNA sequencing analysis revealed gut microbiota modification in SU5416/hypoxia + ABx group. The Firmicutes-to-Bacteroidetes ratio in SU5416/hypoxia rats was significantly higher than that in control and hypoxia rats. Compared with the control microbiota, 14 bacterial genera, including Bacteroides and Akkermansia , increased, whereas seven bacteria, including Rothia and Prevotellaceae , decreased in abundance in SU5416/hypoxia rats. Antibiotic-induced modification of the gut microbiota suppresses the development of pulmonary arterial hypertension. Dysbiosis may play a causal role in the development and progression of pulmonary arterial hypertension.
url https://doi.org/10.1177/2045894020929147
work_keys_str_mv AT takayukijsanada gutmicrobiotamodificationsuppressesthedevelopmentofpulmonaryarterialhypertensioninansu5416hypoxiaratmodel
AT kojihosomi gutmicrobiotamodificationsuppressesthedevelopmentofpulmonaryarterialhypertensioninansu5416hypoxiaratmodel
AT hirokishoji gutmicrobiotamodificationsuppressesthedevelopmentofpulmonaryarterialhypertensioninansu5416hypoxiaratmodel
AT jongukpark gutmicrobiotamodificationsuppressesthedevelopmentofpulmonaryarterialhypertensioninansu5416hypoxiaratmodel
AT akiranaito gutmicrobiotamodificationsuppressesthedevelopmentofpulmonaryarterialhypertensioninansu5416hypoxiaratmodel
AT yumikoikubo gutmicrobiotamodificationsuppressesthedevelopmentofpulmonaryarterialhypertensioninansu5416hypoxiaratmodel
AT asakoyanagisawa gutmicrobiotamodificationsuppressesthedevelopmentofpulmonaryarterialhypertensioninansu5416hypoxiaratmodel
AT takayukikobayashi gutmicrobiotamodificationsuppressesthedevelopmentofpulmonaryarterialhypertensioninansu5416hypoxiaratmodel
AT hidekimiwa gutmicrobiotamodificationsuppressesthedevelopmentofpulmonaryarterialhypertensioninansu5416hypoxiaratmodel
AT rikasuda gutmicrobiotamodificationsuppressesthedevelopmentofpulmonaryarterialhypertensioninansu5416hypoxiaratmodel
AT seiichirosakao gutmicrobiotamodificationsuppressesthedevelopmentofpulmonaryarterialhypertensioninansu5416hypoxiaratmodel
AT kenjimizuguchi gutmicrobiotamodificationsuppressesthedevelopmentofpulmonaryarterialhypertensioninansu5416hypoxiaratmodel
AT junkunisawa gutmicrobiotamodificationsuppressesthedevelopmentofpulmonaryarterialhypertensioninansu5416hypoxiaratmodel
AT nobuhirotanabe gutmicrobiotamodificationsuppressesthedevelopmentofpulmonaryarterialhypertensioninansu5416hypoxiaratmodel
AT koichirotatsumi gutmicrobiotamodificationsuppressesthedevelopmentofpulmonaryarterialhypertensioninansu5416hypoxiaratmodel
_version_ 1724529173149515776